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Terminal Osseous Dysplasia Is Caused by a
Single Recurrent Mutation in the FLNA Gene
Yu Sun,1,11 Rowida Almomani,1,11 Emmelien Aten,1 Jacopo Celli,1 Jaap van der Heijden,1
Hanka Venselaar,2 Stephen P. Robertson,3 Anna Baroncini,4 Brunella Franco,5,6 Lina Basel-Vanagaite,7
Emiko Horii,8 Ricardo Drut,9 Yavuz Ariyurek,1,10 Johan T. den Dunnen,1,10 and Martijn H. Breuning1,*
Terminal osseous dysplasia (TOD) is an X-linked dominant male-lethal disease characterized by skeletal dysplasia of the limbs, pigmen-
tary defects of the skin, and recurrent digital ﬁbroma with onset in female infancy. After performing X-exome capture and sequencing,
we identiﬁed a mutation at the last nucleotide of exon 31 of the FLNA gene as the most likely cause of the disease. The variant
c.5217G>Awas found in six unrelated cases (three families and three sporadic cases) and was not found in 400 control X chromosomes,
pilot data from the 1000 Genomes Project, or the FLNA gene variant database. In the families, the variant segregated with the disease,
and it was transmitted four times from a mildly affected mother to a more seriously affected daughter. We show that, because of
nonrandomX chromosome inactivation, the mutant allele was not expressed in patient ﬁbroblasts. RNA expression of the mutant allele
was detected only in cultured ﬁbroma cells obtained from 15-year-old surgically removed material. The variant activates a cryptic splice
site, removing the last 48 nucleotides from exon 31. At the protein level, this results in a loss of 16 amino acids (p.Val1724_Thr1739del),
predicted to remove a sequence at the surface of ﬁlamin repeat 15. Our data show that TOD is caused by this single recurrentmutation in
the FLNA gene.Terminal osseous dysplasia (MIM 300244) is a rare condi-
tion, characterized by terminal skeletal dysplasia, pigmen-
tary defects of the skin, and recurrent digital ﬁbromata
during infancy. It has been described as a male-lethal
X-linked dominant disease in the previously reported
families and cases.1 Linkage studies mapped the mutation
to Xq27.3-q28.2 However, no disease-causing gene had
been discovered.
In the present study, we examined terminal osseous
dysplasia (TOD) in three families and three sporadic case
individuals (patients 1, 2, and 3 described by Horii,3
Drut,4 and Breuning5). The Dutch family (Figure 1A, family
1) and Italian family (Figure 1A, family 2) have been
described before (Breuning5 and Baroncini6). The third
family (Figure 1A, family 3) has not been reported before
and is nonconsanguineous and of Israeli Arab origin. All
patients, a mother and her two daughters, have normal
cognitive development. The mother (3I:2) suffers from
chronic mild obstructive lung disease and vitamin B12
deﬁciency. Since her childhood, she has had multiple
minor surgeries to remove small skin lesions from her
hands and legs. On clinical examination at the age of 25
yrs, her head circumference was 54 cm (25%–50%), her
height was 170 cm (75%–90%), and her arm span was
171 cm. Her right hand showed brachydactyly of digit
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tion of the fourth digit, with a small lesion on the lateral
aspect of the distal phalanx, and clinodactyly of the ﬁfth
digit (Figure 1B). Her right foot showed a short and highly
implanted fourth digit. There was bilateral widening of
the distal portion of the second–ﬁfth digits. She had no
gingival extra frenulum and no pterygium. A skeletal
X-ray survey revealed unilateral ﬂattening of her vertebral
bodies at L1-L3, secondary right scoliosis, and wedging of
her L1 vertebral body. Her daughter (3II:4) underwent
surgery at 2 mo of age to remove small skin lesions from
her hands, feet, and gingiva. On clinical examination at
the age of 3 yrs, she had a head circumference of 48 cm
(25%–50%), a height of 85 cm (< 3%), and a weight of
11.1 kg (< 3%). She showed hypertelorism—interpupillary
distance of 5.4cm (> 97%), a right epicanthal fold, a
normal palate, an upper and lower accessory frenulum
(Figure 1C), a short neck, and a short thorax. Despite earlier
surgery, she had bilateral skin lesions on her second and
ﬁfth digits and bilateral clinodactyly of the ﬁfth digit
(Figure 1D). Her feet showed a lesion in her third toes
and thickening of the nail of the ﬁfth toes bilaterally.
A skeletal X-ray survey revealed bilateral lytic lesions in
the proximal humerus and the proximal femur, as well as
multiple soft-tissue lesions in her feet and hands. The
youngest daughter (3II:5) was born with multiple lesionsr, 2300RC Leiden, The Netherlands; 2Nijmegen Centre of Molecular Life
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Figure 1. The Pedigrees and the Pheno-
type of Family 3
(A) The pedigrees investigated in this
study. In family 3, XCI patterns show the
silencing of the X chromosome that carries
the mutant allele.
(B) The hands of 3I:2.
(C) Multiple frenula of 3II:4.
(D) The right hand of 3II:4. She has clino-
dactyly and digital ﬁbroma.
(E) The right axillary pterygium of 3II:5.
(F) The right hand of 3II:5.on her hands and feet, including bilateral camptodactyly
of the third digit, and bilateral overriding of the fourth
toe. Echocardiogram at birth showed persistent foramen
ovale. On clinical examination at the age of 6 mo, her
head circumference was 42 cm (25%–50%), her height
was 58.8 cm (< 3%), and her weight was 5.1 kg (< 3%).
She has mild hypertelorism, three brownish pigmented
spots of different sizes (3 mm to 1.5 cm) in her right
temporal groove, mild retrognathia, a right upper acces-
sory frenulum, a cleft palate, a short neck, and a short
thorax. She has a bilateral axillary pterygium (Figure 1E),
which is more severe on the right side. Bilaterally, there
is limited extension of her elbows, with normal supination
and pronation of her hands. In her right hand (Figure 1F),
she had multiple skin lesions on her second–ﬁfth digits,
clinodactyly and lateral deviation of her second and third
digits, and a narrow ﬁfth digit with an absent distal crease.
Her left hand showed skin lesions on her second-fourth
digits. Her second digit was narrow and laterally deviated.
There was camptodactyly of the third-ﬁfth digits, brachy-
dactyly and clinodactyly of the ﬁfth digit, and absence of
a distal crease. In her feet, she had bilateral plantar pits.
The right foot has distal broadening of the second-ﬁfth
toe and brachydactyly of the second and third toe accom-
panied by syndactyly. There was overriding of the third
and fourth toe. On her left foot, the second-ﬁfth toes
were distally broad. She had a overlapping of the second
and fourth toes over her third toe, brachydactyly of the
third toe that was proximally implanted. A skeletal X-ray
survey revealed bilateral lytic lesions of the proximal
humerus, lytic lesions of the left proximal femur, and
multiple soft-tissue lesions. She had underdeveloped tarsal
bones in her feet. The phenotypes from different patients
are summarized in Table 1.The American Journal of HumDNA of patients and family
members were extracted from periph-
eral blood (families 1, 2, and 3), buccal
cells (patient 1), or parafﬁn-embedded
tissue (patients 2 and 3). Two pro-
bands (1II:4 and 2III:5) of the Dutch
and the Italian families were tested
with the X-exome target-enrichment
methodology (SureSelect, Agilent)and next-generation sequencing (Illumina Genome
Analyzer II). The methods used for sequence capture,
enrichment, and elution followed instructions and proto-
cols provided by the manufacturers (SureSelect, Agilent)
with a little modiﬁcation. In brief, 500 ng of DNAwas frag-
mented (Bioruptor, Diagenode) according to manufac-
turer’s instructions to yield fragments from 200 to 300 bp.
Paired-end adaptor oligonucleotides from Illumina were
added to both ends. The DNA-adaptor-ligated fragments
were then hybridized to 250 ng of SureSelect X chromo-
some oligo capture library (SureSelect, Agilent) for 14 hr.
After hybridization, washing, and elution, the elute was
ampliﬁed to create sufﬁcientDNA template for downstream
applications. The eluted-enriched DNA fragments were
sequenced with the Illumina technology platform. We
prepared the paired-end ﬂow cell on the supplied cluster
station, following the instructions of the manufacturer.
The reads were aligned to the reference human genome
(hg 18, NCBI build 36.2) by Bowtie7 (Table S1, available
online). Substitution-variant calling was performed by
searching for positions where a variant nucleotide was
present in more than 30% of the reads. After removing
substitutions present with high frequency in dbSNP, the
variants located in the previously identiﬁed TOD linkage
interval, Xq27.3-q28, were listed in Table 2. From these
variants, c.5217G>A, the only variant shared by the two
patients, in the FLNA gene was selected for further
study for the following reasons: (1) c.5217G>A, the last
nucleotide of exon 31, was predicted to affect splicing
by Human Splicing Finder.8 The score of the splicing
donor site dropped from 91.2 to 80.63, indicating that
the wild-type site may not function as usual. (2) Mutations
in FLNA have been reported to be involved in diseases
showing a partial phenotypic overlap with TOD.9an Genetics 87, 146–153, July 9, 2010 147
Table 1. Clinical Features of the Patients Studied in This Report
1II:4 1III:6 2II:4 2III:5 3I:2 3II:4 3 II:5 Patient 1 Patient 2 Patient 3
Origin
Dutch Dutch Italian Italian Israeli Arab Israeli Arab Israeli Arab Japanese Argentinian Dutch
Age at Onset
1 mo 3 mo 7 mo 2 mo birth 3 mo 4 mo
Pigmentary Skin Anomalies
Face þ þ  þ þ þ þ þ
Scalp   þ 
Fibromatosis
Digital ﬁbromas þ þ  þ þ þ þ þ þ þ
Limbs and Skeletal System
Synadactyly    þ þ þ   
Brachydactyly þ  þ þ þ þ
Clinodactyly  þ þ þ þ
Camptodactyly þ þ
Metacarpal disorganization þ þ  þ þ þ þ
Metatarsal disorganization þ þ  þ þ þ þ þ
Limb long bones anomalies  þ  þ  þ þ þ þ þ
Articular abnormalities þ þ  þ þ þ þ
Facial Features
Cleft palate      þ  
Upslanting palpebral ﬁssures   þ þ
Hypertelorism/Telecanthus þ   þ þ þ
Epicanthic folds   þ þ þ
Coloboma of Iris  þ     
Flat/depressed nasal tip  þ   þ 
Thick lips/Prominent þ  þ
Lower Lip
Papillomata    
Multiple frenula þ þ 
Preauricular pits and tags þ Sanger sequencing results conﬁrmed the presence of
c.5217G>A (Figure 2A) and c.5850T>C (Figure 2B) in all
affected cases (1II:4 and 1III:6) in family 1, as well as
c.5686þ84A>Gfound in an intronbutnot in anunaffected
individual (1I:2). Further evidence came from the analysis
of the Italian family, in whom affected cases (2II:4 and
2III:5) carry exactly the same variant, c.5217G>A, together
withanother exonic variant, c.5814C>T.Unfortunately,we
didnothave access tomaterial frombothparents and there-
fore could not determine whether the mutations occurred
de novo. Notably, families 1 and 2 had two distinct variants
adjacent to the c.5217G>A mutation, making a close and
common ancestor highly unlikely. Finally, upon analysis148 The American Journal of Human Genetics 87, 146–153, July 9, 20of a third TOD family and three unrelated sporadic cases,
we identiﬁed exactly the same c.5217G>A variant again
in all patients, but not in unaffected family members
(1I:2, 3I:1, and 3II:3).
Variant c.5217G>A affects the last nucleotide of exon 31
of the FLNA gene (Figure 2C). At the protein level, it is
not predicted to change the encoded amino acid, but as
the last nucleotide of an exon, it may affect splicing.10–12
RNA was isolated from cultured ﬁbroblasts of arm skin
from 1III:6, removed during a recent orthopaedic proce-
dure under general anesthesia with informed consent.
Cells were cultured in standard medium for human
ﬁbroblasts (Dulbecco’s modiﬁed Eagle’s medium with10
Table 2. List of all Exonic Variants with Low Frequency in the European Population in Xq27.3-Xq28
HGVS Name Gene
Predicted
Function
Predicted Protein
Change 1II:4 2III:5
NM_002025.2:c.1653A>G AFF2 silent p.(¼)  þ
NM_001183.4:c.*461A>C ATP6AP1 30 UTR p.(¼)  þ
NM_001009932.1:c.364G>A DNASE1L1 silent p.(¼) þ 
NM_001110556.1:c.5217G>A FLNA silent p.(¼) þ þ
NM_001110556.1:c.5814C>T FLNA silent p.(¼)  þ rs2070825, high frequency
in a group of multiple populations
NM_001110556.1:c.5850T>C FLNA silent p.(¼) þ  does not segregate with phenotype
NM_004961.3:c.186G>A GABRE silent p.(¼) þ 
NM_005342.2:c.166G>C HMGB3 missense p.(Glu56Gln)  þ
NM_005367.4:c.888A>G MAGEA12 silent p.(¼)  þ
NM_005362.3:c.455G>T MAGEA6 missense p.(Ser152Ile) þ  repetitive region
NM_005365.4:c.92C>A MAGEA9 missense p.(Pro31His) þ  repetitive region
NM_001170944.1:c.468C>T PNMA6B silent p.(¼) þ 
NM_005629.3:c.324A>G SLC6A8 silent p.(¼)  þ
NM_032539.2:c.1002T>C SLITRK2 silent p.(¼)  þ
NM_032539.2:c.309G>A SLITRK2 silent p.(¼)  þ
NM_001009615.1:c.240C>A SPANXN2 silent p.(¼) þ 
NM_014370.2:c.1014G>A SRPK3 silent p.(¼) þ 
NM_006280.1:c.430G>A SSR4 missense p.(Gly144Arg) þ 
All of the HGVS numbers were generated with the use of the longest isoforms if multiple transcripts existed.10% FBS, 1% penicillin/streptomycin, 1% glucose, 1% glu-
tamax) with 5% CO2 in 37
C. RNA was extracted with the
RNeasy Mini Kit (QIAGEN). cDNA was synthesized from
500 ng of total RNA by RevertAid RNaseH-M-MuLV reverse
transcriptase in a total volume of 20 ml according to the
protocol provided by the supplier (MBI-Fermentas). Target
regions were ampliﬁed by RT-PCR with the use of the
primers listed in Table S2. The products were evaluated
with the Bioanalyzer 2100 DNA chip 1000 (Agilent),
according to the manufacturer’s instructions. RNA from
patient ﬁbroblasts showed only normal transcripts, both
transcripts 1 (NM_01456) and 2 (NM_001110556) differ-
ing by insertion of the 24 bp exon 30 in transcript 2.
Although transcript 1 has been reported as the predomi-
nant transcript in controls,13 we detected about equal
expression levels in controls (Figure 3B, lanes 2–4 and 8)
and higher expression of transcript 2 in patient ﬁbroblasts
(Figure 3B, lane 1). Both bands were isolated from the
agarose gel by the Qiaquick Gel Extraction Kit (QIAGEN)
and analyzed by Sanger sequencing. Interestingly, we
detected no expression of the mutant allele. This could
be due to nonsense-mediated decay 14 and/or skewed X
chromosome inactivation (XCI). To test the ﬁrst possi-
bility, the ﬁbroblasts were treated with cycloheximide15
for 4.5 hr followed by RNA analysis using the same proce-
dures as those for RNA from untreated cells. The mutantThe Aallele was still absent in RNA from cycloheximide treated
cells. XCI was analyzed with the Androgen Receptor (AR)
assay.16 The assay showed random XCI in 1I:2 versus
100% XCI of the mutant chromosome in patient 1II:4
(patient 1III:6 was uninformative), indicating that the
mutant allele was inactivated.
Fifteen years ago, at the age of 1 yr, patient 1III:6 had
ﬁbroma tissue from the ﬁfth digits of both hands and the
ﬁfth toe of the left foot surgically removed and stored in
liquid nitrogen. We cultured these cells and analyzed
RNA. In theﬁbromacells,weobserved two sets of twobands
(Figure 3B, lanes 5–7), indicating altered splicing. One set
had the same length as that observed in normal ﬁbroblasts
(Figure3A, transcripts 1 and2), and theother setwas shorter
(Figure 3A, transcripts 3 and 4, faint fromRNAof a tumor in
left ﬁfth ﬁnger and toe; Figure 3B, lanes 6 and 7). Note that
theﬁbroma always contains amixture of tumor andnormal
stromacells. Sequence analysis showedadeletion removing
the last 48 nucleotides of exon 31 (Figure 3C), resulting in
a deletion of 16 amino acids.
To facilitate clinical diagnostics of FLNA genemutations,
we have established a web-based FLNA gene variant
database using the LOVD software.17 In this publicly
available database, we have collected all variants reported
in the literature thus far (83 in total; see FLNA mutation
database), including the variants described here. Themerican Journal of Human Genetics 87, 146–153, July 9, 2010 149
Figure 2. Genomic Structure and Muta-
tion Analysis of FLNA
(A) c.5217G>A was conﬁrmed by Sanger
sequencing in all of the patients. The unaf-
fected family members and controls carry
the homozygous normal allele.
(B) The sequence of c.5850T>C in
family 1.
(C) FLNA is located in Xq28, the target
region of linkage analysis. c.5217G>A
alters the last nucleotide of exon 31 of
FLNA.c.5217G>A variant detected in TOD patients has not been
described before; it is listed neither in dbSNP nor in the
pilot study 1 of the 1000 Genomes Project. Finally, over
400 chromosomes have been sequenced and the mutant
allele was not found (data not shown).
Mutations in FLNA have been reported to cause a wide
range of developmental malformations in the brain, bones,
limbs, heart,18 and other organs19 in human,9 including
periventricular heterotopia (PVNH [MIM 300049])20–24
and otopalatodigital (OPD) spectrum disorders,25 which
include otopalatodigital syndrome type 1 (MIM
311300)26–28 and type 2 (MIM 304120),26,29 frontometa-
physeal dysplasia (MIM 305620),26,30,31 and Melnick-
Needles syndrome (OMIM 309350).26,27 Although each of
the OPD spectrum disorders are characterized by speciﬁc
clinical symptoms, there clearly is a clinical overlap with
TOD, including a generalized bone dysplasia that includes
craniofacial anomalies and anomalies in digits and long
bones.9,32 Interestingly, the most conspicuous symptoms
of TODpatients are skeletal dysplasia of the limbs and recur-
rent digital ﬁbroma, suggesting a signiﬁcant role of the
FLNAmutation in the TOD phenotype.
The FLNA gene encodes a cytoskeletal protein, ﬁlamin A,
which crosslinks actin ﬁlaments into an orthogonal
network and links these to the cell membrane. Within
the cytoskeleton, ﬁlamin A also mediates functions
relating to cell signaling, transcription, and develop-
ment.33 Filamin A consists of two calponin homology
sequences (CH1 and CH2) at the N terminus and connects
with 24 immunoglobin-like ﬁlamin repeats, divided by
two hinges, one between repeats 15 and 16 and one150 The American Journal of Human Genetics 87, 146–153, July 9, 2010between repeats 23 and 24. To check
the stability of ﬁlamin A in patient
cells, protein was extracted from
both ﬁbroblast and ﬁbroma cells.
Immunoblot was performed with
the use of mouse human ﬁlamin A
monoclonal antibody, MAB1680,
from Millipore. No difference in
molecular weight or quantity was
observed. The difference of 18 amino
acids was likely too small to be
distinguished by immunoblot. The
c.5217G>A mutation is located ina highly conserved position at the DNA level, across
a wide range of vertebrate and invertebrate species except
rodent, and found in all ten affected patients from six
different unrelated families. In addition, the mutation
introduced abnormal splicing in ﬁbroma cells. At the
protein level, c.5217G>A encodes the second-to-last
amino acid of repeat 15, which is immediately adjacent
to hinge 1. Recent studies demonstrated repeats 9–15
contain an F-actin binding domain necessary for high
avidity F-actin binding.34 Hinge 1 plays an important
part in maintaining the viscoelastic properties of actin
networks.35 Moreover, this region interacts with many
binding partners, such as TRAF1, TRAF2,36 CaR extracel-
lular Ca2þ receptor,37 and FAP52.38 Because no crystal
structure has yet been described for this region, the crystal
structure of repeat 15 in ﬁlamin B(PDB ﬁle 2 dmb), which
shows the highest identity (58%) with this region of
interest, was used as a template for building a 3D model
(Figure 3D). The model was built with the use of the
WHAT IF and YASARA twinset.39 Repeat 15 consists of
two beta sheets. The in-frame deletion causes the removal
of the top of a beta strand in the middle of one beta sheet,
and of two beta strands at the side of that sheet (gray part
of Figure 3D). These residues are likely to form some kind
of beta strand-like structure and to substantially alter
the structure of the highly conserved tertiary structure of
ﬁlamin repeat 15. Furthermore, this structure will affect
the residues following the beta sheet and linking repeat
15 to hinge 1. Although there is no way to predict what
will happen to those linking residues, we believe it will
affect the overall conformation of the protein and likely
Figure 3. Detection of Alternative Splicing and 3D Protein Model
(A) Diagram of four FLNA transcripts in ﬁbroma cells: transcripts 1 and 2, which carry the 48 bp deletion at the end of exon 31, as well as
the normal transcripts 3 and 4.
(B) RT-PCR result from Agilent 2100 Bioanalyzer. Lane 1 is the product of the ﬁbroblasts of 1III:6, which has a predominant longer iso-
form. Lanes 2–4 and 8 are four control human ﬁbroblasts. Lanes 5–7 show RT-PCR products that were obtained from ﬁbroma cells of
1III:6, the normal bands from two FLNA isoforms, and two extra shorter bands, which are faint in lane 6 (left ﬁfth ﬁnger) and lane 7
(ﬁfth toe of the left foot), whereas lane 5 (right ﬁfth ﬁnger) shows four dark bands.
(C) Sanger sequencing results of c.5858T>C and c.5217G>A in ﬁbroblast and ﬁbroma cells of 1III:6.
(D) The 3D model of FLNA domain 15. The deleted 16 amino acids are marked in gray. Beta strands are marked in red. Green represents
a turn. Yellow indicates a 3/10 helix. Random coils are colored in cyan.inﬂuence the interaction between ﬁlamin A and other
molecules.
The precise mechanism of TOD remains unclear.
However, like other X-linked diseases, XCI might be a
key component of how the disease develops. The develop-
mental role of FLNA is borne out by the presence of the
skeletal and skin malformations at birth. Multiple ﬁbroma
on digits begins to occur in the ﬁrst years, and ﬁbromas
spontaneously stop by the age of ﬁve. Skewed XCI is
known to vary in different tissues and to correlate with
age under the pressure of secondary selection.40 Several
mechanisms may contribute to the skewing, including
stochastic effects, a selective growth advantage of the cell
that carries either the mutated or the normal allele
(secondary cell selection), and genetic processes yielding
preferential inactivation of speciﬁc alleles. Primarily theThe AXCI choice is random, but during cell proliferation, either
in all cells or in a tissue speciﬁc manner, cells that carry an
active mutated allele may have a signiﬁcant disadvantage,
are gradually lost or selected against, and are thus less rep-
resented in the adult female.41 Disorders caused by defects
in the FLNA gene often show a skewed XCI pattern,26
suggesting that cells need normal ﬁlamin to survive.
Several studies in TOD families showed that patients had
skewed XCI, while unaffected individuals had random
inactivation.1,6 We examined the XCI pattern in family 1
(1I:2, 1II:4, and 1III:6) and family 3 (3I:2, 3II:3, 3II:4, and
3II:5; Figure 1A) by AR assay. Apart from the uninformative
patient 1III:6, all of the other patients—1II:4, 3I:2, 3II:4,
and 3II:5—showed extremely skewed XCI (0/100%),
whereas the normal family member 1I:2 showed random
XCI (30/70%), as did 3II:3 (50/50%). Because there wasmerican Journal of Human Genetics 87, 146–153, July 9, 2010 151
no mutant allele detectable in the RNA of normal ﬁbro-
blast, we deduced that 1III:6 also had 100% skewed XCI
with the preferential inactivation of the mutant allele.
We tested the XCI of 2II:4 and 2III:5, and both showed
100% skewing.6 2II:4 was interpreted by the authors as
unaffected. However, we assume that 2II:4 is a carrier of
TOD, given that she has only mild manifestations
(multiple frenula in the mouth). She probably has skewed
XCI at a very early stage. Local XCI patterns may inﬂuence
the severity of the phenotype of carrier females and are
also associated with selective female survival in male-
lethal, X-linked, dominant disorders.
Taken together, these data suggest that TOD is caused by
a unique variant, c.5217G>A (p.Val1724_Thr1739del), in
the FLNA gene. The variant is not found in other databases,
has not been seen in other patients with pathogenic FLNA
variants, segregates with the disease, and is located in
Xq28, where the potential mutated gene causing this
disorder was mapped previously. The mutation was found
in six unrelated families. It will affect splicing, and it causes
a deletion of 16 amino acids at the protein level. The
missing region in the ﬁlamin A protein is hypothesized to
affect or prevent the interaction of ﬁlamin A with other
proteins.
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